#ASCO14 - Poster: Enzalutamide monotherapy: 1-year extended follow-up of a Phase 2 study in hormone-naive prostate cancer patients

CHICAGO, IL USA (UroToday.com) - Presented by Bertrand Tombal,1 Michael Borre,2 Per Rathenborg,3 Patrick Werbrouck,4 Hendrick Van Poppel,5 Axel Heidenreich,6 Peter Iversen,7 Johan Braeckman,8 Jiri Heracek,9 Edwina Baskin-Bey,10 Taoufik Ouatas,10 Frank Perabo,11 De Phung,10 Mohammad Hirmand,12 Matthew R. Smith13 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 tombal poster thumb

1Cliniques Universitaires Saint-Luc, Brussels, Belgium
2Aarhus University Hospital, Aarhus, Denmark
3Herlev University Hospital, Herlev, Denmark
4AZ Groeninge Kortrijk, Kortrijk, Belgium
5UZ Leuven, Leuven, Belgium
6Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany
7Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
8UZ Brussel, Brussels, Belgium
9Univerzita Karlova v Praze, Prague, Czech Republic
10Astellas Pharma Global Development, Leiden, the Netherlands
11Astellas Pharma Global Development, Northbrook, IL USA
12Medivation, Inc., San Francisco, CA USA
13Massachusetts General Hospital Cancer Center, Boston, MA, USA



email news signup